Responders and non-responders to romosozumab treatment.

IF 2.4 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Ayako Tominaga, Keiji Wada, Yoshiharu Kato, Ken Okazaki
{"title":"Responders and non-responders to romosozumab treatment.","authors":"Ayako Tominaga, Keiji Wada, Yoshiharu Kato, Ken Okazaki","doi":"10.1007/s00774-024-01570-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Romosozumab is an anti-sclerostin antibody drug with potent bone formation-promoting and bone resorption-inhibiting properties. It enhances bone mineral density and has a novel effect in preventing fractures. However, there have been reports of non-responders to romosozumab.</p><p><strong>Findings: </strong>If the least significant change is defined as 3%, only 2-12% of patients with spine osteoporosis are non-responders, and romosozumab is highly effective in this population. Low-type 1 amino-terminal propeptide (P1NP) levels during the early treatment phase are associated with non-responders early in treatment. The researchers found a cutoff value of 50.3 μg/L of P1NP in the first month of treatment. In contrast, hip osteoporosis does not respond (54-57% of the time). Low P1NP levels at the start of treatment increase the risk of non-responders. The cutoff value for P1NP was reported as 53.7 μg/L at the beginning of treatment. However, failure to meet these cutoff values does not necessarily indicate that the patient is a non-responder and does not justify a change in drug administration.</p><p><strong>Conclusions: </strong>In spine osteoporosis, romosozumab demonstrates high effectiveness, with approximately 2-12% of patients showing no response. However, in hip osteoporosis, approximately 54-57% do not respond to the treatment with romosozumab.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Mineral Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00774-024-01570-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Romosozumab is an anti-sclerostin antibody drug with potent bone formation-promoting and bone resorption-inhibiting properties. It enhances bone mineral density and has a novel effect in preventing fractures. However, there have been reports of non-responders to romosozumab.

Findings: If the least significant change is defined as 3%, only 2-12% of patients with spine osteoporosis are non-responders, and romosozumab is highly effective in this population. Low-type 1 amino-terminal propeptide (P1NP) levels during the early treatment phase are associated with non-responders early in treatment. The researchers found a cutoff value of 50.3 μg/L of P1NP in the first month of treatment. In contrast, hip osteoporosis does not respond (54-57% of the time). Low P1NP levels at the start of treatment increase the risk of non-responders. The cutoff value for P1NP was reported as 53.7 μg/L at the beginning of treatment. However, failure to meet these cutoff values does not necessarily indicate that the patient is a non-responder and does not justify a change in drug administration.

Conclusions: In spine osteoporosis, romosozumab demonstrates high effectiveness, with approximately 2-12% of patients showing no response. However, in hip osteoporosis, approximately 54-57% do not respond to the treatment with romosozumab.

对罗莫索单抗治疗有反应和无反应。
Romosozumab是一种抗硬化蛋白抗体药物,具有有效的骨形成促进和骨吸收抑制特性。增强骨矿物质密度,对预防骨折有新的作用。然而,也有对romosozumab无反应的报道。研究结果:如果将最不显著的变化定义为3%,则只有2-12%的脊柱骨质疏松症患者无反应,而romosozumab在这一人群中非常有效。治疗早期1型氨基末端前肽(P1NP)水平低与治疗早期无反应相关。研究人员发现,在治疗的第一个月,P1NP的临界值为50.3 μg/L。相比之下,髋关节骨质疏松症没有反应(54-57%的时间)。治疗开始时低P1NP水平会增加无反应的风险。治疗开始时P1NP的临界值为53.7 μg/L。然而,未能达到这些临界值并不一定表明患者无反应,也不能证明改变给药方法是合理的。结论:在脊柱骨质疏松症中,romosozumab显示出高效,约2-12%的患者无反应。然而,在髋部骨质疏松症中,约54-57%的患者对romosozumab治疗无效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Bone and Mineral Metabolism
Journal of Bone and Mineral Metabolism 医学-内分泌学与代谢
CiteScore
6.30
自引率
3.00%
发文量
89
审稿时长
6-12 weeks
期刊介绍: The Journal of Bone and Mineral Metabolism (JBMM) provides an international forum for researchers and clinicians to present and discuss topics relevant to bone, teeth, and mineral metabolism, as well as joint and musculoskeletal disorders. The journal welcomes the submission of manuscripts from any country. Membership in the society is not a prerequisite for submission. Acceptance is based on the originality, significance, and validity of the material presented. The journal is aimed at researchers and clinicians dedicated to improvements in research, development, and patient-care in the fields of bone and mineral metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信